Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Route To Better IVD Commercial Opportunities Outlined In UK Roadmap

Can diagnostics industry stakeholders take advantage of a rare opportunity?

Executive Summary

The COVID-19 pandemic put disease diagnosis in the spotlight for the public and national health care systems alike. A UK report highlights how the IVD industry must capitalize on this unique moment in time.

You may also be interested in...

Medtech SMEs Set Out Regulatory Needs As UK Advances Post-EU System

While the UK continues to develop the future medtech regulatory system for Great Britain, a new market access report recommends how the MHRA should simplify regulatory processes for SMEs.

UK Healthtech SMEs Voice The Challenges They Face In The Market

A multi-stakeholder research and funding program led by deeptech innovation organization CPI has produced two UK medtech industry outlook reports and overseen a £7m innovation funding scheme. Training to help SMEs navigate their way through the medtech regulatory maze is another part the program, the findings of which were released to the public this month.

AI Medical Imaging And Radiotherapy First For UK’s NICE

Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts